Teva Settles Gilead's HIV Drug Patent Suit As Trial Looms

Law360, New York (February 20, 2013, 3:56 PM EST) -- Teva Pharmaceuticals USA Inc. has agreed to a settlement with Gilead Sciences Inc. to end a patent infringement dispute over its planned generic version of antiviral treatment Viread, heading off a trial that was set to begin Wednesday in New York federal court, Gilead said Tuesday.

Under the terms of the deal, which is still tentative and awaits the approval of the court, Teva will be allowed to launch its generic version of the HIV and chronic hepatitis B treatment in December 2017, according to Gilead. Other...
To view the full article, register now.